Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Malignant Melanoma (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 20, 2007
Pay for performance at work
Analysis of: Blue Shield of California to pay $31M in quality bonuses to state medical groups | www.fiercehealthcare.com
Author: GLG Expert Contributor
Pay for performance is here, and being used in actual reimbursements.    This is an example of this in the private payor model.
August 20, 2007
Will combination therapy be better in hormone refractory prostate cancer?
Analysis of: Poniard Pharmaceuticals Announces Initiation of Picoplatin Phase 2 Trial in First-line Treatment of Hormone-Refractory Prostate Cancer in Combination with Docetaxel and Prednisone | money.cnn.com
Author: GLG Expert Contributor
Taxotere with prednisone is the standard first line chemotherapy for hormone refractory prostate cancer based on the results of the TAX 327 trial.   The ongoing phase II trial looks to see if the addition of a platinum based agent to taxotere improves outcomes in hormone refractory prostate...
August 20, 2007
A long way to go
Analysis of: Phase I intravenous trial for anti-cancer drug achieves primary objectives | www.pipelinereview.com
Author: GLG Expert Contributor
Cytopias new agent CY997 has met it's phase I goal to determine MTD and DLT - not a hard task to have done.   Either it's tolerable and safe or not tolerable and not safe.   In this case, the former holds true. However, without more significant clinical data - phase II and III -...
August 20, 2007
What a surprise - another way for CMS to save money
Analysis of: By 2008, Medicare won't pay for hospital errors | www.fiercehealthcare.com
Author: GLG Expert Contributor
Well....we know CMS doesn't have enough money to fund healthcare in perpetuity.   Physicians have been taking reimbursement cuts or lack of raises over the last 5 years.    Realizing you can't squezze enough money out of the physicians, Medican now brilliantly plans to...
August 17, 2007
A new strategy in the treatment of malignant gliomas?
Analysis of: Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab | www.pipelinereview.com
Author: GLG Expert Contributor
Glioblastomas and diffuse pontine gliomas in adults and children are agressive, and nearly universally fatal.  The standard of care today for GBMs is concurrent chemoradiotherapy with Temodar, based on the results of the NCIC trial (Stupp, et al., NEJM, 352:987-96, 2005).   For diffuse...
August 13, 2007
Interesting, but too early to tell
Analysis of: Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration | www.pipelinereview.com
Author: GLG Expert Contributor
There are many theories out there about how angiogenesis affects tumor growth.   One theory is that anti-angiogenic agents emilinate the leakiness of blood vessels, improving flow of blood and chemotherapy to the tumor, essentially getting more of a cytotoxic agent to the target. SPI-1620...
August 10, 2007
Hand washing effect not a surprise
Analysis of: Hand Hygiene Promotion Decreases Healthcare-Associated Infections in Very-Low-Birth-Weight Neonates | www.medscape.com
Author: GLG Expert Contributor
It's not a surprise that washing your hands frequently reduces the spread of infections.    This study verifies what we already know - frequent hand washing between each patient encounter reduces the spread of infections in very low birthweight babies. With aggressive intervention, we...
August 9, 2007
The ultimate personal physician - a growing trend
Analysis of: MDs offer new services, for $3,600 yearly fee | www.boston.com
Author: GLG Expert Contributor
Primary care physicians, often overworked and underpaid for their efforts are seeing a new way to return to the traditional practice style of physcians many years ago, offering appointments lasting more than 6 minutes, and a host of personal touches.   By charging a premium for this service...
August 9, 2007
Don't stop your statins now...
Analysis of: Taking statins may increase cancer risk | www.timesonline.co.uk
Author: GLG Expert Contributor
Certainly, we've had a flurry of bad press over the last few years on blockbuster drugs that had unexpected consequences - Celebrex, ESAs (Epogen, Aranesp, etc...), and most recentlyl Avandia. Statins are some of the most widely used drugs in medicine in a multi-billion dollar industry. We know these...
Taral PatelAugust 9, 2007
ERBITUX
Analysis of: Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program | www.pipelinereview.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next81 to 90 of 159

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203